Selection with a molecUlar PanEl foR Panitunumab Efficacy in K-ras and n-ras wild type metastatic colorectal cancer. This study aims to prospectively define a molecular panel able to identify patients more likely to benefit from the use of first-line panitumumab in combination with mFOLFOX.
Sequential Combo Immuno & Target therapy (SECOMBIT) study. A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/ nivolumab) & combo target therapy (LGX818/MEK162) in patients with metastatic melanoma and BRAF mutation [...]
SeconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status. Phase II Trial. Circulating tumor DNA (Liquid Biopsy) testing, before and during treatment, is used to assess whether the status of selected tumor biomarkers evolve during tumor progression.
Dabradenib and Trametinib in circulating free DNA BRAF mutated positive melanomas: a prospective phase II study. The “liquid biopsy” used as DNA source, represents an alternative approach to identify the clinically relevant cancer mutational landscape when monitoring disease progression and treatment response.
An evaluation of the efficacy beyond progression of vemurafenib combined with cobimetinib associated with local treatment compared to second-line treatment in patients with BRAFV600 mutation-positive metastatic melanoma in focal progression with first-line combined vemurafenib and cobimetinib
Epigenetic modeling/remodeling of cancer metastases and tumor immune contexture to improve efficacy of immunotherapymslmrc662021-02-04T14:17:58+00:00
Cancer progression and metastatization is a complex process in which genetic alterations were initially demonstrated to assume a significant role; however, more recent evidence point to tumor microenvironment (TME) and host's immune system as additional players in cancer progression.
Molecular-genetics testing cooperate in defining the more appropriate and effective diagnostic and therapeutic approaches for the managements of cancer patients. Molecular diagnostics project carried out thanks to an agreement with the University Hospital (AOU) of Sassari.
Personalized approaches for diagnosis and treatment of cancer. The Unit of Cancer Genetics at IRGB-CNR of Sassari is fully focused on precision medicine in oncological field, mostly based on translational research and, to a lesser extent, on basic research. In clinical practice, genomic and epigenomic profiling actually represents a crucial tool for the molecular classification of cancer patients [...]
Finding longevity genes is only one of many goals for gerontologists. An equally important mission is unravelling the genetic processes involved in age-related traits and diseases. IRGB and NIA are focusing their attention on the Mediterranean island of Sardinia. Why? We quote directly from the rationale and background for the initiation of the study in 2001, which also apply to follow-up studies in the course of the Project.
The Sardinian Transcriptome Project The interpretation of GWAS is extremely challenging since most candidate loci fall in non-coding regions and are difficult to interpret. Given the important role of regulatory variation in shaping phenotypic complexity, expression Quantitative Trait Loci (eQTLs) have been proposed as informative intermediate phenotypes between genomic sequence variation and human [...]
The project aims to define the immunological traits whose variation impacts the predisposition to complex diseases and immunosenescence. This is being accomplished by genome wide association studies using ultra-high definition polychromatic flow cytometry of circulating cells The project aims to define the immunological traits whose variation impacts the predisposition to complex diseases and immunosenescence.